Arcview Market Research Predicts Cannabis Sales of $57 Billion by 2027

Posted Leave a commentPosted in Marijuana and the Ecomony

According to Arcview Market Research and its research partner BDS Analytics, over the next 10 years, the legal cannabis industry will see much progress around the globe. Spending on legal cannabis worldwide is expected to hit $57 billion by 2027. The adult-use (recreational) market will cover 67% of the spending; medical marijuana will take up the remaining 33%.

The largest group of cannabis buyers will be in North America, going from $9.2 billion in 2017 to $47.3 billion a decade later. The largest growth spread, however, is predicted within the rest-of-world markets, from $52 million spent in 2017 to a projected $2.5 billion in 2027.

Reposted article from original article by , Forbes 

The worldwide adult recreational cannabis market remains hampered by the United Nations and its 1961 Single Convention on Narcotic Drugs. The Arcview and BDS report believes nothing will be done to change the U.N. attitude until U.S. federal laws legalize marijuana — something Arcview’s CEO, Troy Dayton, believes will happen after the 2020 presidential election.

Still, the main difference between the U.S. and European cannabis markets is that in the U.S., recreational use will dominate sales. With a budget of $1.3 trillion in health care spending, European government-subsidized health care systems will bring the medical cannabis market to dominate Europe and become the largest medical marijuana market in the world.

Tom Adams, editor-in-chief at Arcview Market Research and principal analyst at BDS Analytics, points out that the big news in 2017 was Germany opening up cannabis for medical use in pharmacies. He celebrates a big and constant turnaround in the worldwide cannabis market ahead.

Highlights of the 65-page report “The Road Map to a $57 Billion Worldwide Market” include:

 The initial decision by many U.S. states and Canada to create medical-only cannabis regulations prompted many other countries to act similarly. But California’s and Canada’s willingness to legalize adult recreational use triggered a second wave of laws internationally to increase access to medical cannabis.

 South America has some of the most liberal medical cannabis programs. Led by Brazil, Argentina, Peru and Uruguay (the only country in the world in which adult recreational use is legal for all its citizens), the South American medical cannabis market may grow from $125 million in 2018 to $776 million in 2027.

 Germany is poised to be the leader of the European cannabis market, and Italy is expected to be second with $1.2 billion in sales by 2027. Overall, however, the European cannabis market is not expected to grow as stridently as its potential suggests.

 Australia’s legal cannabis market is forecast to grow from $52 million in 2018 to $1.2 billion in 2027, the 5th largest in the world.

 Israel has a small population and a long history of legal medical marijuana use. It continues as a leader with years in the development of cannabis pharmaceuticals.

 Canada is among the few countries where investors have already shown confidence in the future legality of the cannabis industry; they are betting with billions of dollars pouring into public equity investments.

Cannabis Report

Annual Cannabis Report Projects Massive Growth

Posted Leave a commentPosted in Marijuana and the Ecomony

The 2017 Annual Cannabis Report projects massive growth published by New Frontier Data, probes the industry’s projected market growth, employment opportunities, and marijuana’s potential role as a key revenue source for states and municipalities. Additionally, the report identifies last year (2016) as a turning point for cannabis legalization and contemplates the industry’s uncertain future under the current administration.

reposted from written by  

Nine states that cast their ballots for legalizing medical marijuana during the 2016 election cycle also voted to elect Donald J. Trump as the 45th POTUS, according to a recent Cannabis Report 2017

Dissected and disseminated for ease of ingestion, the company offers one noteworthy disclaimer:

“Projections are based solely on the state markets that passed medical and adult use legalization initiatives as of January 2017, and do not include assumptions for any additional states which may pass legalization measures before 2025.”

Caveat given, according to the company’s 2017  cannabis report, the total legal marijuana market in the U.S. is projected to cultivate some sobering revenue by 2025 – hitting $24.1 billion.

Women's Cannabis Chamber of Commerce

Worth an estimated $4.7 billion in 2016, America’s medical marijuana market is anticipated to top out at $13.2 billion by 2025. And fueled by America’s changing demographics, the report projects that recreational sales will hit $10.9 billion during the same period.

Women's Cannabis Chamber of Commerce


Women's Cannabis Chamber of Commerce

While not all Americans agree that marijuana “should be legalized, regulated, and taxed like cigarettes and alcohol,” the majority of respondents participating in the January survey thought it should. For the survey, Full Circle Research conducted a national poll of 1,671 adults, and found that 55 percent support the outright legalization of recreational marijuana — leaving just nine percent of the respondents in opposition to reform.

Women's Cannabis Chamber of Commerce

Per the report, cannabis offers a potential solution for America’s addiction to pharmaceutical drugs:

“As presented last month, a new report by the National Academies of Sciences, Engineering, and Medicine (NAS) has found conclusive and substantial evidence that cannabis can be effective in treating the symptoms associated with chronic pain, the primary reason for which opioids are prescribed. Furthermore, a 2016 study by the University of Georgia found an 11% reduction in annual drug prescriptions in states legalizing medical cannabis as compared to those which prohibit it.”


Cannabis Report


A noteworthy result of the 2016 general election was the legalization initiatives passed in traditionally red states. After casting their ballots for Donald J. Trump as POTUS, voters in states like ArkansasNorth DakotaLouisiana, and Montana also passed medical marijuana initiatives by a respectable margin.



Women's Cannabis Chamber of CommerceThe Women’s Cannabis Chamber of Commerce moving women beyond empowering and inspiring into action and business success.

Women's Cannabis Chamber of Commerce

Distressed Asset Deals: What Happens When a Cannabis Startup Fails

Posted Leave a commentPosted in Marijuana and the Ecomony, Marijuana Businesses

For a Cannabis Startup it’s simple economics – supply and demand; as the wholesale price of cannabis falls some operators will be edged out of the space. Some will become so-called distressed assets with only three choices: declare bankruptcy (which is tricky), cut their losses, or sell.

In Colorado, wholesale cannabis prices are down 25 percent from 2016, and 73 percent from 2015, which has led to an increase in these types of assets – struggling cannabis startup businesses on the verge of collapse or already non-operational. However, it’s near impossible to tell how many of these assets exist due to the private nature of the industry.

Jason Thomas, CEO of Denver-based Avalon Realty Advisors, said he has handled more than 20 distressed asset real estate deals, and about 15 distressed asset business and license transactions in Colorado since January 2014; ranging from $180,000 short lease deals, to $2 million property sales, to $3 million business sales. Thomas explained that his firm has seen a “marginal” albeit “identifiable” increase in these assets in Colorado over the “last couple of months” from both new and long-standing operators. “Primarily the reason for these distressed sales is typically they run out of cash, or run out of patience, or both.”

“A lot of people tend to underestimate the time and cost involved for ramp up time or opening a new facility or acquiring an existing business,” he said in a phone interview with Ganjapreneur. “It’s unlike most any other industry because you’re creating a manufacture and distribution industry. People don’t understand that until they delve in.”

The distressed asset deals are “complicated,” Thomas said, for a variety of reasons; among them, the federal illegality of cannabis and the lack of defined sales prices – “but deals get done.” He called the deals “the toughest” he has ever worked on, explaining that they can take up to a year to close from the day the contract is signed. Most often, Thomas said, new market entrants have trouble qualifying for licensing or meeting the capital requirements under Colorado’s law.

Read Entire Article written by TG Branfalt at

Marijuana Marketing for Businesses

Marijuana Marketing for Businesses is limited to four entrepreneurs. It is an intense one day workshop that provides you with a personalized marketing plan and strategy, the tools to initiate and maintain it, and marketing resources. The workshop is a cost-effective solution to launching a successful marketing campaign. Marijuana Marketing for Businesses is an investment in the success and growth of your company.

For more information visit The Women’s Cannabis Chamber of Commerce

Women's Cannabis Chamber of Commerce

From Big Pharma to the cannabis industry: Q&A with PharmaCann’s Chris Diorio

Posted Leave a commentPosted in Marijuana and the Ecomony, Marijuana Businesses

Women's Cannabis Chamber of CommerceBig Pharma to the Cannabis Industry: If marijuana business entrepreneurs are wondering whether pharmaceutical professionals might be interested in jumping over to cannabis, the answer is a resounding yes.

Take Chris Diorio, a 25-year pharma industry veteran who recently made such a move, becoming director of research and development for PharmaCann of New York.

PharmaCann has a cultivation and processing site and four vertically integrated dispensaries in New York, as well two grow sites in Illinois, where the company is headquartered.

Diorio’s path to PharmaCann started simply enough during a dinner with two former colleagues, one who previously worked with Diorio at Pfizer and the other a former retail pharmacist. Both were working at Bloomfield Industries, a PharmaCann competitor in the cannabis industry.

Intrigued by that initial conversation, Diorio did some investigating and learned the marijuana is attracting a growing number of pharma professionals. He also discovered cannabis companies that take the right approach likely will have no problem poaching talent from pharmaceutical companies.

Marijuana Business Daily spoke with Diorio about his move to work at a cannabis company, his perceptions of the MJ industry and what companies in this sector can do to lure a top pharma talent.

How did you end up at PharmaCann?

I just dropped (CEO) Teddy Scott a note and said, “Hey, if you’re around, I’d like to chat and see what’s going on over here.” And he said yes.

Fast-forward: We had dinner and I wanted to see what they were really doing and how they were different than what I envisioned a cannabis company would be. It went along with a similar vision to what I shared in the pharmaceutical industry, bringing something that’s beneficial for patients in a whole new light.

How did the company address any doubts you had about entering this industry after coming from Big Pharma?

They said that basically everyone else in the company had the same basic thoughts and questions. They also said to consider what is the upside and the positives of being in a new emerging industry.

Looking back five or six years ago, this wouldn’t have been something I would have even been considering, and many other people probably felt the same way.

But as mentalities have shifted and states have started legalizing, to get in on the ground floor with an emerging business was also very exciting and a good opportunity. Read entire interview at Marijuana Business Daily 

Marketing for Marijuana Businesses